Future Market Insights.png
Global Distance Health Technologies Market is projected to witness a stupendous CAGR of 27%, crossing a revenue of US$ 945 Bn by 2032, up from US$ 88 Bn in 2022 | Expertise by FMI NEWARK, Del, Dec. 21, 2022 (GLOBE NEWSWIRE) -- The global distance health technologies market is predicted to reach a valuation of US$ 945 Bn by 2032 with the market expanding at a CAGR of 27% from...
TYLER PRIZE LOGO _low res.png
Prestigious Environmental Prize Awarded to World Expert on the Links Between Climate Change and Human Health
23 févr. 2022 03h01 HE | Tyler Prize
LOS ANGELES, Feb. 23, 2022 (GLOBE NEWSWIRE) -- The 2022 Tyler Prize for Environmental Achievement – often regarded as the ‘Nobel Prize for the Environment’ – has been awarded to British physician...
Biobanking Global Market
Global Biobanking Market Trends and Forecasts to 2026: Growing Focus on Mainstream Precision Medicine and Rise of Genomic Medicine/Clinical Genomics
22 févr. 2022 05h23 HE | Research and Markets
Dublin, Feb. 22, 2022 (GLOBE NEWSWIRE) -- The "Biobanking: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. This report aims to provide a comprehensive...
22157.jpg
Global Pharma and Biotech Preclinical Stage Partnering Deals Directory 2021: Comprehensive Access to Deals and Contract Documents for Over 2,400 Deals
14 janv. 2022 04h08 HE | Research and Markets
Dublin, Jan. 14, 2022 (GLOBE NEWSWIRE) -- The "Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021" report has been added to ResearchAndMarkets.com's offering. ...
Aceragen Pic.png
Aceragen Announces $3.5 Million Development Award from Cystic Fibrosis Foundation to Progress Novel Therapy for CF-Related Exacerbations
06 janv. 2022 09h00 HE | Aceragen
Raleigh-Durhan, NC, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aceragen, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for orphan diseases with high unmet medical need, today...
Aceragen Pic.png
Aceragen’s wholly-owned subsidiary, Arrevus, awarded $45 million funding agreement from the Department of Defense’s Defense Threat Reduction Agency for Development of ACG-701 as Medical Countermeasure Against Melioidosis
05 janv. 2022 09h00 HE | Aceragen
Raleigh-Durham, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Arrevus, Inc., a clinical-stage biopharmaceutical company developing therapies for orphan infectious diseases with high unmet medical need, ...
22157.jpg
Insights on Pharma, Biotech & Diagnostics Industry from 2015 to 2021
10 nov. 2021 04h03 HE | Research and Markets
Dublin, Nov. 10, 2021 (GLOBE NEWSWIRE) -- The "Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2015-2021" report has been added to ResearchAndMarkets.com's...
Logo.jpg
ProPhase Labs to Host Second Quarter 2021 Financial Results Conference Call on Friday, August 13, 2021 at 11:00 a.m. Eastern Time
09 août 2021 08h30 HE | ProPhase Labs, Inc.
GARDEN CITY, NY , Aug. 09, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, will hold a conference call on Friday, August 13, 2021...
Logo.jpg
ProPhase Labs Acquires Digital Covid Vaccination and Testing “Passport” Solution
30 mars 2021 17h10 HE | ProPhase Labs, Inc.
 New Reporting App Simplifies Documentation of User Vaccination and Covid Testing Statue – Easily Enables Clear Access to Air/Rail/Bus Travel, Concert & Sporting Events GARDEN CITY, NY, March...
Logo.jpg
ProPhase Labs to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Wednesday, March 31, 2021 at 4:30 p.m. Eastern Time
15 mars 2021 08h30 HE | ProPhase Labs, Inc.
GARDEN CITY, NY, March 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, will hold a conference call on Wednesday, March 31, 2021...